Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomark DiagnosticsSTU:20B 27 3-Year ROIIC % is -192.31 as of Mar. 2026. GuruFocus rates STU:20B with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Biomark Diagnostics ranks better than 79.8% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Biomark Diagnostics's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was -192.31%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Biomark Diagnostics's 3-Year ROIIC % or its related term are showing as below:
STU:20B's 3-Year ROIIC % is ranked better than 79.8% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs STU:20B: -192.31
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Biomark Diagnostics 3-Year ROIIC % Related Terms
Biomark Diagnostics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Biomark Diagnostics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:20B vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Biomark Diagnostics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's 3-Year ROIIC % falls into.
Biomark Diagnostics's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.919 (Mar. 2026) - -1.182 (Mar. 2023) )
/
( 0.68 (Mar. 2026) - 0.835 (Mar. 2023) )
=
0.263
/
-0.155
=
-169.68%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Biomark Diagnostics (STU:20B) has a 3-Year ROIIC % of -192.31 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Biomark Diagnostics and its competitors. According to the industry distribution chart, Biomark Diagnostics ranks #41 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 20.2%.
Is Biomark Diagnostics' 3-Year ROIIC % too high?
Biomark Diagnostics' current 3-Year ROIIC % is -192.31. Based on the distribution chart, Biomark Diagnostics ranks #41 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Biomark Diagnostics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #41 out of 203 companies for 3-Year ROIIC %. This places Biomark Diagnostics in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Biomark Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomark Diagnostics's current 3-Year ROIIC % is -192.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (STU:20B) has a current 3-Year ROIIC % of -192.31. The current 3-Year ROIIC % is -192.31. Biomark Diagnostics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Biomark Diagnostics (STU:20B), the current 3-Year ROIIC % is -192.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
27GF Score
Get the complete analysis for STU:20B
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:20B has been successfully added to your 
